Mechanism of Action:
- Dual agonist of glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptors
- Stimulates insulin secretion and suppresses glucagon production
- Slows gastric emptying and reduces appetite
- Increases energy expenditure through thermogenesis activation
Recommended for:
- Patients with obesity (BMI ≥ 30 kg/m² or ≥ 27 kg/m² with comorbidities)
- Type 2 diabetes patients with inadequate glycemic control
- Individuals with metabolic syndrome and insulin resistance
- Ineffectiveness of monotherapy with other antidiabetic agents
Research and Studies:
Phase 2 clinical studies demonstrate:
- 12-15% weight loss over 24 weeks of therapy
- 1.8-2.2% reduction in HbA1c levels in diabetic patients
- Improvement in lipid profile and reduction in inflammation markers
- Good tolerability and safety with long-term use
- Advantages over GLP-1 monoagonists in weight reduction
- Chronic obesity treatment in adults
- Type 2 diabetes as monotherapy or in combination
- Metabolic syndrome with impaired glucose tolerance
- Complex therapy of insulin resistance
The drug is dissolved in appropriate volume of sterile water for injections and administered subcutaneously in the abdominal area, thigh or shoulder. Starting dose is 2.5 mg once weekly, with gradual titration to maximum dose of 10 mg per week. Injections are recommended to be done on the same day of the week.
Contraindications:
- Type 1 diabetes mellitus
- Personal or family history of multiple endocrine neoplasia type 2 (MEN 2)
- History of acute pancreatitis
- Severe renal or hepatic insufficiency
- Pregnancy and lactation period
Side Effects:
- Nausea, vomiting, diarrhea (especially at therapy initiation)
- Decreased appetite and dyspeptic phenomena
- Headache and dizziness
- Injection site reactions
- Risk of hypoglycemia when combined with other antidiabetic agents
